Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma

Kosuke Watari, Ayumi Nishitani, Tomohiro Shibata, Masaki Noda, Akihiko Kawahara, Jun Akiba, Yuichi Murakami, Hirohisa Yano, Michihiko Kuwano, Mayumi Ono

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Although recent studies facilitate the identification of crucial genes and relevant regulatory pathways, therapeutic approaches against advanced HCC are insufficiently effective. Therefore, we aimed here to develop potent therapeutics to provide a reliable biomarker for the therapeutic efficacy in patients with HCC. To this end, we first compared the cytotoxic effects of various anti-cancer drugs between well differentiated (HAK-1A) and poorly differentiated (HAK-1B) cell lines established from a single HCC tumor. Of various drug screened, HAK-1B cells were more sensitive by a factor of 2,000 to the mTORC1 inhibitors (rapalogs), rapamycin and everolimus, than HAK-1A cells. Although rapalogs inhibited phosphorylation of mTOR Ser2448 in HAK-1A and HAK-1B cells, phosphorylation of mTOR Ser2481 was specifically inhibited only in HAK-1B cells. Silencing of Raptor induced apoptosis and inhibited the growth of only HAK-1B cells. Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin. Treatment with everolimus markedly inhibited the growth of tumors induced by poorly differentiated HAK-1B and KYN-2 cells and phosphorylation of mTOR Ser2481 in vivo. To our knowledge, this is the first study showing that the phosphorylation of mTOR Ser2481 is selectively inhibited by rapalogs in mTORC1-addicted HCC cells and may be a potential reliable biomarker for the therapeutic efficacy of rapalogs for treating HCC patients.

Original languageEnglish
Pages (from-to)47403-47417
Number of pages15
JournalOncotarget
Volume7
Issue number30
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Hepatocellular Carcinoma
Phosphorylation
Sirolimus
Neoplasms
Biomarkers
Raptors
Therapeutics
Cell Line
Regulator Genes
Growth
Pharmaceutical Preparations
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. / Watari, Kosuke; Nishitani, Ayumi; Shibata, Tomohiro; Noda, Masaki; Kawahara, Akihiko; Akiba, Jun; Murakami, Yuichi; Yano, Hirohisa; Kuwano, Michihiko; Ono, Mayumi.

In: Oncotarget, Vol. 7, No. 30, 01.01.2016, p. 47403-47417.

Research output: Contribution to journalArticle

Watari, K, Nishitani, A, Shibata, T, Noda, M, Kawahara, A, Akiba, J, Murakami, Y, Yano, H, Kuwano, M & Ono, M 2016, 'Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma', Oncotarget, vol. 7, no. 30, pp. 47403-47417. https://doi.org/10.18632/oncotarget.10161
Watari, Kosuke ; Nishitani, Ayumi ; Shibata, Tomohiro ; Noda, Masaki ; Kawahara, Akihiko ; Akiba, Jun ; Murakami, Yuichi ; Yano, Hirohisa ; Kuwano, Michihiko ; Ono, Mayumi. / Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 30. pp. 47403-47417.
@article{bb4ddfe9dcd148ee90476a129d1494f3,
title = "Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Although recent studies facilitate the identification of crucial genes and relevant regulatory pathways, therapeutic approaches against advanced HCC are insufficiently effective. Therefore, we aimed here to develop potent therapeutics to provide a reliable biomarker for the therapeutic efficacy in patients with HCC. To this end, we first compared the cytotoxic effects of various anti-cancer drugs between well differentiated (HAK-1A) and poorly differentiated (HAK-1B) cell lines established from a single HCC tumor. Of various drug screened, HAK-1B cells were more sensitive by a factor of 2,000 to the mTORC1 inhibitors (rapalogs), rapamycin and everolimus, than HAK-1A cells. Although rapalogs inhibited phosphorylation of mTOR Ser2448 in HAK-1A and HAK-1B cells, phosphorylation of mTOR Ser2481 was specifically inhibited only in HAK-1B cells. Silencing of Raptor induced apoptosis and inhibited the growth of only HAK-1B cells. Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin. Treatment with everolimus markedly inhibited the growth of tumors induced by poorly differentiated HAK-1B and KYN-2 cells and phosphorylation of mTOR Ser2481 in vivo. To our knowledge, this is the first study showing that the phosphorylation of mTOR Ser2481 is selectively inhibited by rapalogs in mTORC1-addicted HCC cells and may be a potential reliable biomarker for the therapeutic efficacy of rapalogs for treating HCC patients.",
author = "Kosuke Watari and Ayumi Nishitani and Tomohiro Shibata and Masaki Noda and Akihiko Kawahara and Jun Akiba and Yuichi Murakami and Hirohisa Yano and Michihiko Kuwano and Mayumi Ono",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10161",
language = "English",
volume = "7",
pages = "47403--47417",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "30",

}

TY - JOUR

T1 - Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma

AU - Watari, Kosuke

AU - Nishitani, Ayumi

AU - Shibata, Tomohiro

AU - Noda, Masaki

AU - Kawahara, Akihiko

AU - Akiba, Jun

AU - Murakami, Yuichi

AU - Yano, Hirohisa

AU - Kuwano, Michihiko

AU - Ono, Mayumi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Although recent studies facilitate the identification of crucial genes and relevant regulatory pathways, therapeutic approaches against advanced HCC are insufficiently effective. Therefore, we aimed here to develop potent therapeutics to provide a reliable biomarker for the therapeutic efficacy in patients with HCC. To this end, we first compared the cytotoxic effects of various anti-cancer drugs between well differentiated (HAK-1A) and poorly differentiated (HAK-1B) cell lines established from a single HCC tumor. Of various drug screened, HAK-1B cells were more sensitive by a factor of 2,000 to the mTORC1 inhibitors (rapalogs), rapamycin and everolimus, than HAK-1A cells. Although rapalogs inhibited phosphorylation of mTOR Ser2448 in HAK-1A and HAK-1B cells, phosphorylation of mTOR Ser2481 was specifically inhibited only in HAK-1B cells. Silencing of Raptor induced apoptosis and inhibited the growth of only HAK-1B cells. Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin. Treatment with everolimus markedly inhibited the growth of tumors induced by poorly differentiated HAK-1B and KYN-2 cells and phosphorylation of mTOR Ser2481 in vivo. To our knowledge, this is the first study showing that the phosphorylation of mTOR Ser2481 is selectively inhibited by rapalogs in mTORC1-addicted HCC cells and may be a potential reliable biomarker for the therapeutic efficacy of rapalogs for treating HCC patients.

AB - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Although recent studies facilitate the identification of crucial genes and relevant regulatory pathways, therapeutic approaches against advanced HCC are insufficiently effective. Therefore, we aimed here to develop potent therapeutics to provide a reliable biomarker for the therapeutic efficacy in patients with HCC. To this end, we first compared the cytotoxic effects of various anti-cancer drugs between well differentiated (HAK-1A) and poorly differentiated (HAK-1B) cell lines established from a single HCC tumor. Of various drug screened, HAK-1B cells were more sensitive by a factor of 2,000 to the mTORC1 inhibitors (rapalogs), rapamycin and everolimus, than HAK-1A cells. Although rapalogs inhibited phosphorylation of mTOR Ser2448 in HAK-1A and HAK-1B cells, phosphorylation of mTOR Ser2481 was specifically inhibited only in HAK-1B cells. Silencing of Raptor induced apoptosis and inhibited the growth of only HAK-1B cells. Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin. Treatment with everolimus markedly inhibited the growth of tumors induced by poorly differentiated HAK-1B and KYN-2 cells and phosphorylation of mTOR Ser2481 in vivo. To our knowledge, this is the first study showing that the phosphorylation of mTOR Ser2481 is selectively inhibited by rapalogs in mTORC1-addicted HCC cells and may be a potential reliable biomarker for the therapeutic efficacy of rapalogs for treating HCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84982843821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982843821&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10161

DO - 10.18632/oncotarget.10161

M3 - Article

VL - 7

SP - 47403

EP - 47417

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -